Market Whales and Their Recent Bets on NTRA Options

Investors with significant funds have taken a bullish position in Natera NTRA, a development that retail traders should be aware of.

This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in NTRA usually indicates foreknowledge of upcoming events.

Today, Benzinga's options scanner identified 12 options transactions for Natera. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 91% being bullish and 0% bearish. Of all the options we discovered, 11 are puts, valued at $1,304,670, and there was a single call, worth $28,000.

Expected Price Movements

Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $160.0 to $160.0 for Natera over the recent three months.

Insights into Volume & Open Interest

In terms of liquidity and interest, the mean open interest for Natera options trades today is 137.5 with a total volume of 14,736.00.

In the following chart, we are able to follow the development of volume and open interest of call and put options for Natera's big money trades within a strike price range of $160.0 to $160.0 over the last 30 days.

Natera Call and Put Volume: 30-Day Overview

Noteworthy Options Activity:

About Natera

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Current Position of Natera

• Currently trading with a volume of 643,596, the NTRA's price is up by 3.63%, now at $172.49.
• RSI readings suggest the stock is currently may be approaching overbought.
• Anticipated earnings release is in 75 days.

Expert Opinions on Natera

In the last month, 3 experts released ratings on this stock with an average target price of $192.0.

Turn $1000 into $1270 in just 20 days?

20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * An analyst from Piper Sandler persists with their Overweight rating on Natera, maintaining a target price of $200. * An analyst from JP Morgan persists with their Overweight rating on Natera, maintaining a target price of $200. * Maintaining their stance, an analyst from Morgan Stanley continues to hold a Overweight rating for Natera, targeting a price of $176.

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Natera options trades with real-time alerts from Benzinga Pro.